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Involvement of GJB2 noncoding regions in hearing loss (HL) has not been extensively investigated. However, three noncoding
mutations, c.-259C>T, c.-23G>T, and c.-23+1G>A, were reported. Also, c.-684 -675del, of uncertain pathogenicity, was found
upstream of the basal promoter. We performed a detailed analysis of GJB2 noncoding regions in Portuguese HL patients
(previously screened for GJB2 coding mutations and the common GJB6 deletions) and in control subjects, by sequencing the basal
promoterandﬂankingupstreamregion,exon1,and3’UTR.Allindividualsweregenotypedforc.-684 -675deland14SNPs.Novel
variants (c.-731C>T,c.-26G>T, c.∗45G>A, andc.∗985A>T)were found in controls. A hearing individual homozygous forc.-684 -
675del was for the ﬁrst time identiﬁed, supporting the nonpathogenicity of this deletion. Our data indicate linkage disequilibrium
(LD) between SNPs rs55704559 (c.∗168A>G) and rs5030700 (c.∗931C>T) and suggest the association of c.[∗168G;∗931T] allele
with HL. The c.∗168A>G change, predicted to alter mRNA folding, might be involved in HL.
1.Introduction
About two hundred GJB2 mutations causing nonsyndrom-
ic hearing loss (NSHL) have been reported (http://www
.hgmd.org/)[ 1]. Most GJB2 mutations described so far
localize to the coding region (totally included within exon
2), which is routinely analysed upon the study of GJB2 in
HL patients. Also involved in HL, two deletions, del(GJB6-
D13S1830) [2–4]a n dd e l ( GJB6-D13S1854) [5] disrupt the
GJB6 gene which codes for connexin-30, and it is thought
that they may ablate a GJB2 cis-regulatory sequence [5–
7]. This putative element is likely to be ablated by a
third deletion, del(chr13:19,837,344–19,968,698), localized
upstream of GJB2 and GJB6 [8, 9].
Along with GJB2 coding region, the noncoding ﬁrst exon
and donor splice site have been analysed in several studies,
and two pathogenic mutations, c.-23G>T( e x o n1 )[ 10]a n d
c.-23+1G>A (intron) [11], both in the donor splice site,
have been identiﬁed. The c.-23+1G>A mutation (commonly
known as IVS1+1G>A), shown to impair splicing [12], has
been identiﬁed in several cases, being particularly frequent
in Czech Republic, Turkey, and Hungary [13–15].
A few studies have investigated, in addition to exon 1,
the noncoding region immediately upstream of this exon,
including the basal promoter [14, 16–21].
Houseman and coworkers [16] analysed HL patients het-
erozygous for c.101T>C (p.Met34Thr), in which no second
GJB2 coding mutation had been detected, and identiﬁed a2 Genetics Research International
monoallelic10bp deletion, c.-684 -675del (ﬁrstlydesignated
-493del10), upstream of the basal promoter. The deletion
was also present in other hearing impaired individuals as
well as in control individuals, with or without c.101T>C.
However, c.-684 -675del homozygosity was only observed in
c.101T>C homozygous patients. The fact that in the control
population 22 of the 25 (88%) c.101T>Ch e t e r o z y g o t e s
carried the deletion suggested the existence of LD between
c.101T>C and c.-684 -675del, later demonstrated by Zoll
and coworkers [22]. Transcription was observed from alleles
harbouring in cis the deletion and the variant c.101T>C,
derived from keratinocytes and cell lines. However, eventual
subtle diﬀerences would not have been detected, since this
was not a quantitative analysis [16]. To date, the role of c.-
684 -675del in HL has remained uncertain.
More recently, a pathogenic basal promoter mutation,
c.-259C>T (ﬁrstly designated -3438C>T) was identiﬁed,
in trans with c.250G>A (p.Val84Met), in a Portuguese
HL patient, highlighting the relevance of screening GJB2
noncoding regions in nonelucidated cases [18].
In the present study, we have analysedthe basal promoter
and the ﬂanking upstream region, as well as the exon 1
and the 3 UTR of the GJB2 gene in 89 Portuguese HL
patients. The same analysis was conducted on 91 normal
hearing control individuals from the Portuguese popula-
tion.
2. Methods
2.1. Subjects. Eighty-nine Portuguese HL patients previously
screened for mutations in the GJB2 coding region and
acceptor splice site (by SSCP and/or sequencing) and for
the del(GJB6-D13S1830) and del(GJB6-D13S1854) GJB6
deletions (using the methodology described in [5]) were
enrolled in this study. Eight patients were heterozygous
for a GJB2 coding mutation: c.71G>A (p.Trp24X; n=1),
c.35delG (n=3), c.109G>A (p.Val37Ile; n=1), c.380G>A
(p.Arg127His; n=1), c.457G>A (p.Val153Ile; n=2), and
one patient was heterozygous for the c.-22-12C>T variant
(apparently a polymorphism; dbSNP accession number
rs9578260). No patient harboured either of the known GJB6
deletions. The HL was nonsyndromic in all patients, except
for one of them, who presented with Waardenburg syn-
drome. The patient was heterozygous for the controversial
c.457G>A mutation and was thus included in the study.
The patients presented with bilateral, mild to profound HL,
and were either familial or sporadic cases. The familial cases
predominantly showed a recessive pattern of inheritance.
All patients were audiologically evaluated by pure tone
audiometry.
The control sample was composed of 91 Portuguese
individuals with apparent normal hearing. The status
regarding c.101T>C GJB2 variant of those control indi-
viduals harbouring the c.-684 -675del, here referred, had
been previously investigated, by sequencing, as part of an
unpublished work. The status of the entire GJB2 coding
region is not known for the vast majority of the 91 control
individuals, which were blindly included in this study (and
not based on their eventually available GJB2 coding region
status).
Informed consent was obtained from all the participants.
2.2. Genetic Analysis. In all individuals, we have sequenced
a region of about 0.7kb immediately upstream of the exon
1 (which includes the basal promoter), the exon 1, and the
whole 3 UTR. The region upstream of the exon 1, plus exon
1 and donor splice site, was ampliﬁed in a 1009bp amplicon,
using the pair of primers PF2 5 -CgTTCgTTCggATTg-
gTgAg-3  and PR1 5 -CAgAAACgCCCgCTCCAgAA-3 ,a s
previously described [18]. The amplicons were sequenced
using the primers PF2 and PF1 5 -ggCTCAAAggAACTA-
ggAgATCg-3 . When necessary, primers PR1 and PR2 5 -
ggAgACTgggAAAgTTACgg-3  were used for sequencing.
The 3 UTR (plus the last 90 nucleotides and stop codon)
wasampliﬁedin3overlappingfragmentsusingthefollowing
three pairs of primers: 3UTRaF 5 -gCAgTgTCTggAATT-
TgCATC-3 ,3 U T R a R5  -AggCACTggTAACTTTgTCC-3 ,
3UTRbF 5 -CACgTTAAAggTgAACATTgg-3 ,3 U T R b R5  -
CgACAgAAACTTCTCCCTC-3 , 3UTRcF 5 -gTAgCCAgC-
ATCggAAAgAAC-3 , 3UTRcR 5 -ACTCTggCAACTTAC-
CCATTg-3 .The3 UTRPCRproductsweresequencedusing
the respective ampliﬁcation forward primers.
2.3. DNA Sequence Variants and SNPs Description. Descrip-
tion of variants follows the HGVS recommendations, and is
based on the GJB2 reference sequences accessed through the
following links:
(1) https://research.cchmc.org/LOVD/refseq/GJB2
codingDNA.html;
(2) https://research.cchmc.org/LOVD/refseq/GJB2
intron 01.html;
(3) https://research.cchmc.org/LOVD/refseq/GJB2
upstream.html;
(4) https://research.cchmc.org/LOVD/refseq/GJB2
downstream.html.
These sequences show 100% identity with the
NM 004004.5 (link 1) and NG 008358.1 (links 2, 3, and 4)
NCBI reference sequences.
Novel variants were submitted to dbSNP and the respec-
tive reference SNP (rs) accession numbers are provided
within the text.
SNPs are referred to by the dbSNP reference SNP (rs)
accession number whenever it was available, and by the
HGVS recommended designation, relative to the foremen-
tioned reference sequences.
2.4. Genotyping and Statistical Analysis. We have genotyped
all individuals for the c.-684 -675del deletion; three SNPs
in the promoter (rs9550621 (c.-484T>C), rs73431557 (c.-
410T>C), rs9552101 (c.-369A>G)); ten SNPs in the 3 UTR
(c.∗1C>T, rs3751385 (c.∗84T>C), rs7337074 (c.∗104A>T),
rs7329857 (c.∗111C>T), rs55704559 (c.∗168A>G),
rs5030700 (c.∗931C>T), rs1050960 (c.∗1067G>T), rs7623
(c.∗1152G>A), rs11841182 (c.∗1197T>A), and rs7988691Genetics Research International 3
(c.∗1277T>C)); one SNP downstream of the 3 UTR
(rs11839674 (c.∗1447G>A)).
For the sake of simplicity, when describing the compos-
ite genotypes regarding SNPs rs73431557 (c.-410T>C),
rs3751385 (c.∗84T>C), rs55704559 (c.∗168A>G), and
rs5030700 (c.∗931C>T), the genotype at each position,
indicated in order from 5  to 3 ,i sd e s i g n a t e db yA ,C ,G ,o r
T if homozygous, or by a code letter, according to IUPAC
nucleotide ambiguity code, if heterozygous.
The allelic frequencies regarding deletion c.-684 -675del
and the 14 SNPs, were determined in the control population
and used to test for Hardy-Weinberg equilibrium. The chi-
square test was used to compare the allelic frequencies of
the patients with those of the normal hearing individuals.
Allelic frequencies of the control sample for the 14 SNPs
wereusedtocalculatepairwiselinkagedisequilibriumvalues.
Testing for Hardy-Weinberg equilibrium, calculation of
pairwise linkage disequilibrium values, and haplotype esti-
mation (through the expectation maximization algorithm),
were performed using SNPAnalyzer 1.2A online software
(http://snp.istech.info/snp/SNPAnalyzer.html).
2.5. Analysis of mRNA Folding. Mfold (http://mfold.rna
.albany.edu/?q=mfold/RNA-Folding-Form)[ 23]w a s
used to assess the eﬀect of alleles c.[∗168A;∗931C],
c.[∗168G;∗931T], c.[∗168A;∗931T], and c.[∗168G;∗931C]
on the folding of GJB2 mRNA (template sequence:
ENST00000382848, retrieved from Ensembl). For each se-
quence the lowest free-energy structure was considered.
3. Results andDiscussion
In the current study, 89 Portuguese HL patients, previously
screened for mutations in the GJB2 coding region and
acceptor splice site (80 patients presenting no mutation,
plus eight heterozygous for coding mutations and one
heterozygous for the noncoding variant c.-22-12C>T),
and 91 hearing individuals were analyzed as regards the
noncoding region immediately upstream of the exon 1
(which includes the basal promoter), the exon 1, and
the whole 3 UTR of GJB2 gene. All individuals were
also genotyped for c.-684 -675del and 14 SNPs localized
therein.
3.1. DNA Sequence Variants. No additional GJB2 variant was
found in any of the eight patients previously found to be
heterozygous for a coding GJB2 mutation or in the patient
heterozygous for the c.-22-12C>T noncoding variant.
Among the remaining 80 patients, six of them pre-
sented noncoding variants, which had already been reported
(Table 1).
One patient, presenting with profound HL was het-
erozygous for the donor splice site c.-23+1G>A mutation.
The patient may just be a carrier, or other GJB2 or GJB6
mutation might remain undetected. One other patient,
presenting with moderate to severe HL, harboured in
heterozygosity the c.-216T>G variant, located within the
basal promoter, between two GT boxes [24, 25]. This
variant was previously identiﬁed in two HL patients, also
in heterozygosity [26]. The c.-45C>A variant in exon 1
was found in heterozygosity in one individual with severe
HL. This variant was referred, by Wilch and coworkers
[8], as an SNP at position +94 in exon 1. These authors
observedexpressionoftheGJB2alleleharbouringthevariant
but, since a quantitative comparison with wild-type allele
was not performed, a possible contribution to HL cannot
be excluded. Three aﬀected individuals (two heterozygous
and one homozygous) harboured the deletion c.-684 -
675del.
No novel putative pathogenic noncoding mutation has
been found in the patients, which might be due to the low
numberofmonoallelicindividualsandthesmallsamplesize.
It is also possible that, simply, such mutations are very rare
in our population.
Among controls, four novel noncoding variants were
identiﬁed: c.-731C>T, c.-26G>T, c.∗45G>A, and c.∗985A>T
(rs112400198, rs112875543, rs112399473, and rs111729919,
resp.). Each of these variants was identiﬁed only once,
in heterozygosity, and in diﬀerent individuals (Table 1).
The hearing individual harbouring the novel c.-
731C>T variant was also heterozygous for the
recessive c.670A>C (p.Lys224Gln) 1mutation (https://
.cchmc.org/LOVD/; phase unknown). One control indi-
vidual harboured the c.-45C>Ae x o n1v a r i a n ti nh e t e r -
ozygosity (Table 1). Interestingly, we found one control
subject homozygous for c.-684 -675del (Table 1), which
is, to our knowledge, the ﬁrst case described to date of a
normal hearing individual presenting this genotype. This
individual did not harbour the c.101T>C mutation. Our
ﬁnding, together with the previous report of transcription
from alleles harbouring c.-684 -675del [16] suggests the
nonpathogenicity of the deletion. In addition, six normal
hearing heterozygotes for the deletion were also identiﬁed
(Table 1), with one also heterozygous for c.101T>C.
It should be noted that the pathogenic basal promoter
mutation c.-259C>T, identiﬁed for the ﬁrst time in a
Portuguesefamily[18],wasnotfoundamongthe89patients
and91normalhearingindividualshereanalysed,andneither
was it identiﬁed in the other studies which analysed the
basal promoter [14, 16–21]. Therefore, known occurrence
of c.-259C>T continues to be restricted to that Portuguese
family.
3.2. Genotypic Data and Statistical Analysis. The allelic
frequencies and Hardy-Weinberg equilibrium status regard-
ing the deletion c.-684 -675del and the 14 noncod-
ing SNPs were determined (Table 2; see Supplementary
Table 1 in Supplementary Material available online at doi:
10.4061/2011/827469).
The allelic frequencies of the deletion c.-684 -675del in
patients and controls are not statistically diﬀerent (Table 2).
Theallelicfrequencyobservedforthisdeletioninourcontrol
population is close to the one found among the British
controlpopulation[16],andhigherthantheonedetermined
in the German control population [22].
The allelic frequencies regarding SNPs c.-410T>C,
c.∗84T>C, c.∗168A>G, and c.∗931C>T, were statistically4 Genetics Research International
Table 1: GJB2 variants identiﬁed in this study. Novel variants are in italic. BP: basal promoter; Ex 1: exon 1; DSS: donor splice site; Ex 2:
exon 2; CR: coding region; 3 UTR: 3  untranslated region.
Variant Location Patients (n = 89) Controls (n = 91)
Heterozygote Homozygote Heterozygote Homozygote
c.-731C>T5   of the BP 0 0 1 0
c.-684 -675del 5  of the BP 2161
c.-216T>GB P 1 000
c.-45C>AE x 1 1 0 1 0
c.-26G>TE x 1 0 0 1 0
c.-23+1G>AD S S 1 000
c.670A>C (p.Lys224Gln) Ex 2 (CR) 0 0 1 0
c.∗45G>A3  UTR 0 0 1 0
c.∗985A>T3  UTR 0 0 1 0
Table 2: Diﬀerences in the allelic frequencies, regarding c.-684 -675del and 14 SNPs, between patient and control samples (chi-square test).
ND: not determined: chi-square test could not be performed for SNPs with an expected value <5, or for SNPs which both alleles were
observed in only one sample. Four SNPs present statistically signiﬁcant diﬀerences in allelic frequencies between patients and controls (P
values < 0.05, in bold).
Variant/SNP Alleles Patients (n = 178 alleles) Controls P value
Observed Expected (n = 182 alleles)
c.-684 -675del wt 174 170.18 174 0.162043
c.-684 -675del 4 7.82 8
rs9550621 c.-484 C 162 165.29 169 0.338941
c.-484 T 16 12.71 13
rs73431557 c.-410 C 41 26.41 27 0.002089
c.-410 T 137 151.59 155
rs9552101 c.-369 A 20 19.56 20 0.916103
c.-369 G 158 158.44 162
c.∗1C>T c.∗1 C 177 178 182 ND
c.∗1T 1 0 0
rs3751385 c.∗84 C 129 139.86 143 0.04734
c.∗84 T 49 38.14 39
rs7337074 c.∗104 A 174 177.02 181 ND
c.∗104 T 4 0.98 1
rs7329857 c.∗111 C 174 177.02 181 ND
c.∗111 T 4 0.98 1
rs55704559 c.∗168 A 154 170.18 174 3.33E-09
c.∗168 G 24 7.82 8
rs5030700 c.∗931 C 155 169.20 173 9.18E-07
c.∗931 T 23 8.80 9
rs1050960 c.∗1067 G 19 19.56 20 0.893155
c.∗1067 T 159 158.44 162
rs7623 c.∗1152 A 165 165.29 169 0.93373
c.∗1152 G 13 12.71 13
rs11841182 c.∗1197 A 2 0 0 ND
c.∗1197 T 176 178 182
rs7988691 c.∗1277 C 178 176.04 180 ND
c.∗1277 T 0 1.96 2
rs11839674 c.∗1447 A 2 0 0 ND
c.∗1447 G 176 178 182Genetics Research International 5
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Figure 1: Frequencies, in patients (n = 89) and controls (n = 91), of the composite genotypes concerning SNPs c.-410T>C, c.∗84T>C,
c.∗168A>G, and c.∗931C>T; R = A/G heterozygosity; Y = C/T heterozygosity (based on IUPAC nucleotide ambiguity code).
Table 3: (a) Estimated haplotype frequencies, based on the control
population, concerning SNPs c.-410 T>C, c.∗84T>C, c.∗168A>G,
and c.∗931C>T. (b) Relationship between the estimated prevalent
alleles regarding positions c.∗168 and c.∗931, and SNPs c.-410T>C
and c.∗84T>C.
(a)
Haplotype Frequency
TCAC 0.7802
CTAC 0.0989
TTAC 0.0714
CTGT 0.0440
CCAT 0.0055
(b)
Allele (c.∗168; c.∗931) c.-410 T>Cc . ∗84T>C
AC 89.6% T 82.1% C
GT 100% C 100% T
diﬀerent between patient and control groups (Table 2).
By sorting both patients and controls into groups reﬂect-
ing the genotypes for these four SNPs altogether, eleven
composite genotypes were evidenced (Figure 1). Compari-
son of the genotypic frequencies in controls and patients
promptly revealed an increased frequency in patients of the
genotypes YYRY and CTRY, both heterozygous for SNPs
c.∗168A>Ga n dc . ∗931C>T. Also, the genotype YCAC was
identiﬁed in four patients but not found in controls. On
the contrary, a decrease was observed in the frequency of
the three genotypes that are most represented in controls—
TCAC, TYAC, and YYAC. Each of the remaining genotypes
was scarcely represented in both controls and patients (0%–
2%),andtheirfrequencydidnotvarymorethan2%between
the two groups; only 3% of controls and 4% of patients
belong to one of these genotypes.
We also observed that, regarding SNPs c.∗168A>Ga n d
c.∗931C>T, nearly all individuals analysed (178/180) were
either c.[=;=]+[=;=]o rc . [ ∗168A>G(+)∗931C>T], which
results from LD between these two SNPs (Supplementary
Table 2, SNP pair 8:9). Interestingly, the overrepresenta-
tion of c.[∗168A>G(+)∗931C>T] genotype among patients,
when comparing to hearing controls, is statistically very
signiﬁcant (χ2 = 28.159; P = 3.4 E-06), thus accounting
for the statistically signiﬁcant diﬀerences in the allelic
frequencies of these two SNPs between patients and hearing
controls.
The statistically signiﬁcant diﬀerences also observed
in the allelic frequencies of SNPs c.-410T>Ca n d
c.∗84T>C seems to be due to the diﬀerential association6 Genetics Research International
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Figure 2: Eﬀect of c.∗168A>Ga n dc . ∗931C>T changes in the 3 UTR on GJB2 mRNA folding. (a) c.∗168A and c.∗168G; (b) c.∗931C and
c.∗931T. The mRNA folding associated with each variant is the same regardless of the allele present at the other position, therefore only one
example for each variant is provided.
of their variants with the estimated predominant alleles
c.[∗168A+∗931C] and c.[∗168G+∗931T] (Tables 3(a) and
3(b)). This fact is in accordance with the observed LD
between the two SNPs and SNPs c.∗168A>Ga n dc . ∗931C>T
(Supplementary Table 2, SNP pairs 2:8, 2: 9, 5:8, and
5:9).
It should be noticed that the presence of genotype YCAC
among patients lends some contribute to the diﬀerence in
allelic frequencies between patients and controls regarding
SNP c.-410T>C.
T h ef a c tt h a tY C A Cg e n o t y p ei sn o tr e p r e s e n t e di n
91 control individuals while it occurs in 4/89 patients is
noteworthy. The presence of genotype YCAC implies the
presence of haplotype CCAC, which frequency is of at least
2,2% among patients, and estimated to be null in the control
population (as inferred from Table 3(a)). In order to validate
a possible association of haplotype CCAC with HL analysis
of larger samples of patients and normal hearing individuals
is necessary. Interestingly, one of the four patients with the
referred composite genotype is a c.457G>Ah e t e r o z y g o t e
(phase unknown).
3.3. 3 UTR Variants and mRNA Folding. Our ﬁndings sug-
gest that the c.[∗168G;∗931T] allele might have a deleterious
eﬀect, contributing to HL. We have used Mfold [23]t op r e -
dict the eﬀect of alleles c.[∗168A;∗931C], c.[∗168G;∗931T],
c.[∗168A;∗931T], and c.[∗168G;∗931C] on mRNA folding.
The change c.∗168A>G, regardless of genotype at position
c.∗931, was predicted to alter mRNA folding. On the
contrary, the change c.∗931C>T, regardless of genotype at
position c.∗168, is not predicted to alter mRNA folding
(Figure 2).
The c.∗168A was predicted to be located in an internal
loop of a stem-loop structure (Figure 2). Regulatory motifs
in mRNA 3 UTR seem to function in the context of speciﬁc
secondary structure [27]. Stem-loop structures occurring in
the 3 UTR have been implicated in gene expression, with
roles at the level of mRNA stability (e.g., the SLDE of
G-CSF gene [28], the CDE of TNF-alpha gene [27, 29],
the complex structure integrating three C-rich elements of
alpha-globin gene, the histone mRNA 3  terminal stem-
loops, and the IRE of TFRC gene [27]) or translation (e.g.,
the common 30–37 nucleotide long element present in
the target mRNAs of TIA-1, a translational repressor [30],
and the SECIS element [27]). The disruption of the pre-
dicted stem-loop structure and/or other adjacent stem-loop
structures (Figure 2), induced by the c.∗168A>Gc h a n g e ,
m i g h tl e a dt od e r e g u l a t i o no ft h eGJB2 gene expression,
thus being a contributor to the hearing loss phenotype.
It should be stressed that mRNA folding predictions are
fallible. This fact notwithstanding, the simple change of
sequence, without aﬀecting the secondary structure, could
conceivably disrupt a binding site for a trans-acting factor,
also leading to gene expression deregulation. Regarding theGenetics Research International 7
c.∗931C>T variant, despite the predictions that c.∗931C
occurs in a helix and that the change from C to T does not
have structural implications, the in vivo situation might be
diﬀerent. Functional studies involving constructs containing
a reporter gene’s coding sequence fused with GJB2 3 UTR
could help elucidating the functional signiﬁcance of these
two sequence variants.
In this study, of a total of 15 patients presenting either
a GJB2 coding mutation or a noncoding variant, 14 do not
harbour either the c.∗168A>G or the c.∗931C>T changes,
whereas one patient, heterozygous for the controversial
c.380G>A mutation, is a compound heterozygote regard-
ing SNPs c.∗168A>Ga n dc . ∗931C>T (phase unknown).
Therefore, our data do not allow withdrawal of conclusions
concerning a putative role of the two 3 UTR variants in
the HL of some monoallelic patients. In this regard, the
investigation of the genotypes regarding c.∗168A>Ga n d
c.931C>T variants in larger samples of monoallelic patients
would be interesting. Finally, the ﬁnding of one c.∗168G
homozygote (a c.∗931C>T heterozygote, and carrying no
GJB2 sequence variant) in our patient cohort, might further
support a possible role of c.∗168G in HL.
4. Conclusion
This study suggests the association of the noncoding SNPs
c.∗168A>Ga n dc . ∗931C>Tw i t hH L .T h ec . ∗168A>G
change is predicted to alter mRNA folding, suggesting a
putativeroleofthisSNPinthepathology.Ourdataalsopoint
to a possible association with HL of the haplotype CCAC,
comprising SNPs c.-410T>C, c.∗84T>C, c.∗168A>G, and
c.∗931C>T, respectively. However, this observation requires
validation through analysis of a larger number of subjects.
The technique of targeted sequence capture and massively
parallel sequencing makes it very easy and cost-eﬀective to
screen large numbers of genes, and might cover noncoding
sequences of some of them, such as GJB2. This approach
could prove to be very useful for genetic diagnosis in cases of
NSHL [31], with predictable beneﬁts for genetic counselling
of the aﬀected families.
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